TY - JOUR
T1 - A novel endotoxin antagonist attenuates tumor necrosis factor-α secretion
AU - Dahlberg, Peter S.
AU - Acton, Robert D.
AU - Battafarano, Richard J.
AU - Uknis, Marc E.
AU - Ratz, Craig A.
AU - Johnston, Jennifer W.
AU - Haseman, Judith R.
AU - Gray, Beulah H.
AU - Dunn, David L.
N1 - Funding Information:
1Supported by RO1 Grant GM32414 from the National Institutes of Health (DLD) and a grant from the North Star Research Foundation (BHG).
PY - 1996/6
Y1 - 1996/6
N2 - Twenty-seven amino acid peptides with sequences corresponding to a proposed endotoxin binding region of bactericidal permeability increasing protein (BPI): 1) inhibit lipopolysaccharide induced macrophage tumor necrosis factor-α (TNF-α) secretion, 2) have bactericidal activity against gram-negative bacteria, and 3) protect mice from a lethal lipopolysaccharide (LPS) challenge. Unfortunately, peptides have a short half-life in vivo. Therefore, we have chemically conjugated the BPI based peptide, BG38, to a larger carrier protein, keyhole limpet hemocyanin (KLH), and characterized its ability: 1) to inhibit LPS induced macrophage TNF-α secretion and 2) to decrease plasma endotoxin and TNF-α levels following an i.v. injection of E. coli 0111:B4 LPS. BG38-KLH inhibited cultured macrophage TNF-α secretion in response to LPS derived from four pathogenic strains of gram-negative bacteria in a dose dependent manner (>90% inhibition at 50 μg/ml, P < 0.05 Student's t test). BG38-KLH also decreased serum endotoxin (>90%, P < 0.05 Student's t test) and peak TNF-α levels (>30% inhibition, P < 0.05 Student's t test) following E. coli LPS challenge in a murine gram-negative bacterial sepsis model. Novel endotoxin antagonists based upon a small domain of BPI represent promising reagents for the treatment of serious gram-negative bacterial infections.
AB - Twenty-seven amino acid peptides with sequences corresponding to a proposed endotoxin binding region of bactericidal permeability increasing protein (BPI): 1) inhibit lipopolysaccharide induced macrophage tumor necrosis factor-α (TNF-α) secretion, 2) have bactericidal activity against gram-negative bacteria, and 3) protect mice from a lethal lipopolysaccharide (LPS) challenge. Unfortunately, peptides have a short half-life in vivo. Therefore, we have chemically conjugated the BPI based peptide, BG38, to a larger carrier protein, keyhole limpet hemocyanin (KLH), and characterized its ability: 1) to inhibit LPS induced macrophage TNF-α secretion and 2) to decrease plasma endotoxin and TNF-α levels following an i.v. injection of E. coli 0111:B4 LPS. BG38-KLH inhibited cultured macrophage TNF-α secretion in response to LPS derived from four pathogenic strains of gram-negative bacteria in a dose dependent manner (>90% inhibition at 50 μg/ml, P < 0.05 Student's t test). BG38-KLH also decreased serum endotoxin (>90%, P < 0.05 Student's t test) and peak TNF-α levels (>30% inhibition, P < 0.05 Student's t test) following E. coli LPS challenge in a murine gram-negative bacterial sepsis model. Novel endotoxin antagonists based upon a small domain of BPI represent promising reagents for the treatment of serious gram-negative bacterial infections.
UR - http://www.scopus.com/inward/record.url?scp=0029951814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029951814&partnerID=8YFLogxK
U2 - 10.1006/jsre.1996.0220
DO - 10.1006/jsre.1996.0220
M3 - Article
C2 - 8661170
AN - SCOPUS:0029951814
SN - 0022-4804
VL - 63
SP - 44
EP - 48
JO - Journal of Surgical Research
JF - Journal of Surgical Research
IS - 1
ER -